immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 for Glioblastoma

Multi-target therapeutic cancer vaccine IMA950 to enter second clinical phase I study for glioblastoma, the most aggressive form of brain cancer

03-Jun-2010 - immatics biotechnologies GmbH announced that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR), National Cancer Institute (NCI), USA. The Agreement covers the clinical development of immatics’ therapeutic cancer vaccine IMA950 which is to be evaluated in the field ...

Bavarian Nordic announces partnership with National Cancer Institute in the US and obtains rights to a new vaccine candidate

14-Aug-2008 - Bavarian Nordic's US subsidiary, BN ImmunoTherapeutics has entered into a scientific partnership with the National Cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and Bavarian Nordic will jointly develop new immunotherapies for ...

U.S. NCI Files for Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN

16-May-2007 - Oncolytics Biotech Inc. announced that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial for patients with metastatic melanoma using systemic administration of REOLYSIN(R), Oncolytics' proprietary ...

TopoTarget and CuraGen Initiate NCI-Sponsored Phase II Trial of PXD101 for Ovarian Cancer

16-Nov-2006 - TopoTarget A/S and CuraGen Corporation announced the initiation of patient dosing in a Phase II clinical trial evaluating the antitumor activity of intravenous PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of ovarian cancer. This trial is being sponsored by the ...

Southwest Oncology Group Opens New Lymphoma Trial with CuraGen's and TopoTarget's PXD101

28-Aug-2006 - CuraGen Corporation and TopoTarget A/S announced the Southwest Oncology Group, a national clinical trials cooperative group, has just opened a Phase II clinical trial to test the effects of a new investigational agent on aggressive B-cell lymphoma. The agent, PXD101, will be evaluated in patients ...

CuraGen and TopoTarget Initiate NCI-sponsored Phase I Clinical Trial of PXD101 and Azacitidine

10-Aug-2006 - CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase I clinical trial evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with azacitidine for the treatment of advanced hematologic ...

Transgene to Collaborate in a Novel Melanoma Treatment Under a Cooperative Research and Development Agreement

22-Jun-2006 - Transgene S.A. announced that it has executed a Cooperative Research and Development Agreement (CRADA) Letter of Intent with the National Cancer Institute (NCI) for the development of novel melanoma treatments with Steven A. Rosenberg, M.D., Ph.D., Chief, Surgery Branch. Dr. Rosenberg has ...

Nventa announces positive HspE7 data from NCI-sponsored clinical trial in HIV-positive patients

First Clinical Evidence that HspE7 May Have Activity in Immunocompromised Patients

19-Jun-2006 - Nventa Biopharmaceuticals Corporation announced results, recently published in the journal AIDS, from a clinical trial to test HspE7, an investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, on patients with high-grade anal intraepithelial neoplasia (AIN), or ...

Lorus announces down regulation of GTI-2040 molecular target in breast cancer clinical study

Publication shows rapid reduction in target gene expression in responding tumor tissue

24-Apr-2006 - Lorus Therapeutics Inc. announced publication of data demonstrating decreased expression of the molecular target for its antisense drug, GTI-2040, in a Phase II breast cancer clinical trial. The article titled "Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 ...

Oncolytics Biotech Inc. Announces Commencement of Solicitation Process for Clinical Trials

24-Jan-2006 - Oncolytics Biotech Inc. announced that the Cancer Therapy Evaluation Program (CTEP), part of the U.S. National Cancer Institute ("NCI"), has issued a solicitation for Letters of Intent with respect to the conduct of two human clinical trials using REOLYSIN(R), a proprietary formulation of the ...